Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Interest in the relationships between the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents has increased over recent years. Since the appearance 2 years ago of our first article describing terminology in PK/PD, the field has continued to expand rapidly, urgently requiring an update. This paper describes in a uniform manner the use of PK/PD expressions for antimicrobial agents, and their units.

[1]  K. Drlica.  The mutant selection window and antimicrobial resistance. , 2003, The Journal of antimicrobial chemotherapy.

[2]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.

[3]  J. Andrews,et al.  Determination of minimum inhibitory concentrations. , 2001, The Journal of antimicrobial chemotherapy.

[4]  G. Drusano,et al.  Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.

[5]  Jerome J. Schentag,et al.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.

[6]  L. Danziger,et al.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens , 1997, Antimicrobial agents and chemotherapy.

[7]  P. Maire,et al.  Dosage Regimens of Antibacterials , 1996 .

[8]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[9]  Jerome J. Schentag,et al.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar , 1994, Antimicrobial Agents and Chemotherapy.

[10]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[11]  J. Spivey.  The postantibiotic effect. , 1992, Clinical pharmacy.

[12]  Jerome J. Schentag,et al.  Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.

[13]  O. Cars,et al.  Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro , 1991, Antimicrobial Agents and Chemotherapy.

[14]  B. Guglielmo,et al.  Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens , 1988, Antimicrobial Agents and Chemotherapy.

[15]  S. Barriere,et al.  Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. , 1985, The Journal of antimicrobial chemotherapy.

[16]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[17]  V. Lorian.  Antibiotics in laboratory medicine , 2005 .

[18]  Johan W Mouton,et al.  Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics , 2005, Clinical pharmacokinetics.

[19]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .